Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
ConditionSugammadex
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, Davis
About this trial
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
Eligibility criteria
Qualifiers
age greater than 18 years
scheduled for an elective laparoscopic gastric bypass procedure
Disqualifiers
age less than 18 years
pregnancy
prisoners
significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
Trial design
Treatments tested in this trial
- Quantitative Neuromuscular Function Monitoring
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov